Sesamin Cancer Research Results

SES, SSM, Sesamin: Click to Expand ⟱
Features:

Sesamin — is a naturally occurring, lipid-soluble furofuran lignan and one of the principal bioactive compounds in sesame (Sesamum indicum) seeds and sesame oil. Classified as a natural polyphenolic lignan, sesamin (SES; also SSM) exhibits anti-inflammatory, antioxidant, antiproliferative, pro-apoptotic, and antimetastatic activities in experimental models. Its principal anticancer mechanisms involve inhibition of NF-κB and STAT3 signaling, suppression of PI3K/AKT survival pathways, modulation of apoptosis, and inhibition of epithelial–mesenchymal transition (EMT). Sesamin is distinct from the related sesame lignans sesamolin and sesamol, although these compounds share some biological activities.

Primary mechanisms (ranked):

  1. NF-κB inhibition: Suppresses IKK/IκBα-dependent NF-κB activation and nuclear signaling, reducing transcription of inflammatory and tumor-survival mediators including COX-2, Bcl-2, survivin, cyclin D1, MMP-9, and VEGF.
  2. IL-6/STAT3 inhibition: Reduces IL-6 production and STAT3 phosphorylation, suppressing tumor proliferation, survival, invasion, and cancer stem-like characteristics. Particularly relevant to gallbladder and bladder cancer models.
  3. Apoptosis induction: Promotes cancer-cell apoptosis through modulation of Bcl-2-family proteins, caspase activation, and p53-associated signaling in responsive models.
  4. PI3K/AKT and MAPK modulation: Attenuates proliferative and survival signaling through PI3K/AKT and context-dependent regulation of ERK, JNK, and p38 MAPK pathways.
  5. EMT and metastasis suppression: Increases E-cadherin and decreases TWIST, vimentin, and matrix metalloproteinases in responsive cancer models, reducing migration, invasion, and stem-like characteristics.
  6. Chemosensitization: Enhances cisplatin sensitivity in experimental gallbladder cancer stem-like cells and demonstrates combination-treatment activity in other preclinical cancer models.
  7. ROS and NRF2 regulation (secondary): Generally reduces oxidative stress and can activate NRF2-dependent cytoprotective genes in nonmalignant inflammatory or injury models. Cancer-cell redox responses are model-dependent and should not be assumed equivalent.
  8. Angiogenesis suppression: Reduces NF-κB-associated VEGF expression and angiogenic signaling in selected experimental tumor systems.
  9. Lipid and cardiovascular regulation: Modulates oxidative and inflammatory pathways associated with lipid metabolism and vascular function. Small human randomized trials suggest modest improvements in LDL cholesterol, total cholesterol, and systolic blood pressure.

Bioavailability / PK relevance: Sesamin is orally absorbed but undergoes hepatic oxidative metabolism, particularly through CYP2C9 and CYP1A2, followed by conjugation of its metabolites. Human administration of 50 mg/day combined sesamin and episesamin demonstrated peak sesamin plasma concentrations approximately 5 hours after dosing, with no significant accumulation during repeated administration. Its lipophilic nature favors administration with dietary fat, although improved clinical anticancer exposure has not been established. CYP2C9 and CYP2C19 inhibition has been demonstrated in vitro, creating potential drug-interaction concerns, particularly with narrow-therapeutic-index medications.

In-vitro vs systemic exposure relevance: Anticancer experiments commonly employ sesamin concentrations in the tens to hundreds of micromolar range. For example, gallbladder cancer studies used 11–100 µM and demonstrated cisplatin sensitization at 33.3 µM. These experimental concentrations should not be assumed achievable as sustained unbound plasma concentrations following ordinary dietary or supplemental intake. Human pharmacokinetic data confirm absorption but do not establish clinically effective anticancer exposure. Active metabolites, protein binding, tissue distribution, and achievable tumor concentrations remain important translational uncertainties.

Clinical evidence status: Cancer: Preclinical evidence from cell cultures and animal models; no established human anticancer efficacy or validated oncology dosing regimen. Chemosensitization: Preclinical only, not an established clinical adjunct. Cardiometabolic: Small human randomized controlled trials, with a seven-trial meta-analysis involving 212 participants reporting modest reductions in total cholesterol, LDL cholesterol, and systolic blood pressure. Sesamin is not an approved anticancer drug.

Sesamin: Mechanistic Effects on Cancer and Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB / IKK / IκBα ↓ NF-κB activation, nuclear p65, COX-2, survivin, Bcl-2, cyclin D1 ↓ Inflammatory NF-κB signaling (context-dependent) R/G Antiproliferative, anti-inflammatory, pro-apoptotic One of the best-characterized mechanisms. Inhibits constitutive and inducible NF-κB activity across several experimental tumor models.
2 IL-6 / STAT3 / TWIST ↓ IL-6, p-STAT3, TWIST, survival signaling ↓ Excess inflammatory signaling (context-dependent) R/G Reduced tumor survival, stemness, and invasion Supported by gallbladder cancer stem-like cell experiments and bladder cancer models. Particularly important for resistance-associated phenotypes.
3 Apoptosis / Bcl-2 / Caspases ↓ Bcl-2 and survivin; ↑ apoptotic signaling and caspase activation ↔ or ↓ Injury-related apoptosis (context-dependent) G Induction of programmed cancer-cell death Apoptosis involves several model-dependent pathways. Selectivity toward malignant cells has not been demonstrated clinically.
4 PI3K / AKT / mTOR ↓ AKT-associated survival signaling (model-dependent) ↔ or ↑ Protective AKT signaling (context-dependent) R/G Reduced proliferation and survival Pathway response varies across experimental models. AKT activation can contribute to NRF2-mediated protection in nonmalignant cells.
5 EMT / E-cadherin / Vimentin ↑ E-cadherin; ↓ vimentin, TWIST, migration ↔ G Reduced invasion, metastasis-related behavior, and stem-like phenotype Direct experimental support in gallbladder carcinoma stem-like cells, including suppression of tumor-sphere formation.
6 Chemosensitization / Cisplatin ↑ Cisplatin sensitivity; ↓ drug-resistant cell survival ↔ Uncertain G Potential enhancement of chemotherapy efficacy Gallbladder cancer stem-like cell experiments demonstrated chemosensitization with 33.3 µM sesamin and 4 µM cisplatin. Clinical combination efficacy and safety remain unverified.
7 MAPK / JNK / ERK / p38 ↔ Context-dependent phosphorylation and apoptotic signaling ↑ Protective ERK signaling in selected injury models R/G Regulation of proliferation, stress responses, and apoptosis Not a uniformly inhibitory mechanism. The direction depends on cell type, concentration, and experimental conditions.
8 MMP-2 / MMP-9 / Invasion ↓ MMP-2 or MMP-9, migration and invasion ↔ Uncertain G Antimetastatic activity MMP-2 suppression has been associated with lincRNA-p21/STAT3 modulation in bladder cancer models; MMP-9 suppression is associated with NF-κB inhibition.
9 VEGF / Angiogenesis ↓ VEGF-associated signaling ↔ Context-dependent G Suppression of tumor-associated angiogenic signaling Primarily preclinical evidence. Direct clinical inhibition of tumor angiogenesis has not been demonstrated.
10 ROS / Oxidative Stress ↔ Model-dependent oxidative stress response ↓ ROS and oxidative injury in protective models R/G Secondary redox regulation and cytoprotection Antioxidant protection in normal tissues is better characterized than a consistent pro-oxidant anticancer mechanism. Do not assume ROS elevation is required for sesamin-induced cancer-cell death.
11 NRF2 / Antioxidant Defense ↔ Context-dependent; potential survival implications ↑ NRF2 transcriptional activity and downstream antioxidant defenses R/G Protection against oxidative and inflammatory injury Demonstrated in epithelial oxidative-stress and colitis models. NRF2 induction is not established as a principal anticancer mechanism and may have different consequences in tumor cells.
12 Lipid Metabolism / Vascular Function ↔ Not a validated direct anticancer pathway ↓ LDL cholesterol, total cholesterol, systolic blood pressure in pooled clinical studies G Modest cardiometabolic effects Human evidence exists but is limited by small trials and heterogeneous interventions. Outcomes do not demonstrate cancer prevention or treatment efficacy.
13 Clinical Translation Constraint High experimental concentrations; uncertain tumor exposure Oral absorption; hepatic metabolism; possible CYP interactions G Limits extrapolation from preclinical studies Human PK confirms absorption, but systemic and intratumoral exposures required for anticancer efficacy are not established. CYP2C9/CYP2C19 interactions remain a safety consideration, especially with warfarin, phenytoin, and other sensitive substrates.

TSF: P: 0–30 min R: 30 min–3 hr G: >3 hr



Scientific Papers found: Click to Expand⟱
9276- SES, SSM,    Sesamin manifests chemopreventive effects through the suppression of NF-kappa B-regulated cell survival, proliferation, invasion, and angiogenic gene products
- in-vitro, Var, NA
TumCP↓, Apoptosis↑, Bcl-2↓, survivin↓, cycD1/CCND1↓, Inflam↓, COX2/PTGS2↓, TumCI↓, MMP9↓, ICAM-1↓, NF-kB↓,
9277- SES, SSM,    Differentiation therapy: sesamin as an effective agent in targeting cancer stem-like side population cells of human gallbladder carcinoma
- vitro+vivo, Gall, SGC996
AntiCan↑, CSCs↓, NF-kB↓, IL5↓, p‑STAT3↓, Twist↓, Vim↓, E-cadherin↑, Dose↝,
9278- SES, SSM,    Antitumor Effects of Sesamin via the LincRNA-p21/STAT3 Axis in Human Bladder Cancer: Inhibition of Metastatic Progression and Enhanced Chemosensitivity
- vitro+vivo, Bladder, UMUC3 - in-vitro, Bladder, 5637
tumCV↓, MMP2↓, STAT3↓, TumCMig↓, TumCI↓, ChemoSen↑, TumVol↓, TumW↓, Ki-67↓, Synergy↑,
9279- SES, SSM,    Sesamin exhibits potential food-drug interactions through the inhibition of cytochrome P450s and human UDP-glucuronosyltransferases in vitro
- Review, Var, NA
*Inflam↓, *antiOx↓, *hepatoP↓, *TC↓, *CYP2C9↓, *CYP2C19↓, *other↝,
9280- SES, SSM,    A comprehensive review on the anti-cancer properties and mechanisms of action of sesamin, a lignan in sesame seeds (Sesamum indicum)
- Review, Var, NA
AntiCan↑, TumCP↓, Apoptosis↑, Inflam↓, TumMeta↓, angioG↓, ROS↓, TumAuto↓,
9281- SES, SSM,  LIGs,    A comprehensive review on the anti-cancer properties of sesame lignans: chemical composition, molecular mechanisms and prospects
- Review, Var, NA
Ingr↝, ChemoSen↑, *Sleep↑, *antiOx↑, *GPx↑, *GSR↑, *GSH↑, *MDA↓, selectivity↑, TumCCA↑, cycD1/CCND1↓, CDK2↓, P53↑, COX2/PTGS2↓, TumCP↓, Apoptosis↑, DNAdam↑, cl‑Casp3↑, NF-kB↓, ROS↑, MMP↓, VEGF↓, MMP9↓, Hif1a↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,   ROS↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 3,   Bcl-2↓, 1,   cl‑Casp3↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

STAT3↓, 1,   p‑STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,   P53↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   cycD1/CCND1↓, 2,   Ki-67↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   Ki-67↓, 1,   TumCP↓, 3,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   MMP2↓, 1,   MMP9↓, 2,   TumCI↓, 2,   TumCMig↓, 1,   TumMeta↓, 1,   Twist↓, 1,   Vim↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 2,   ICAM-1↓, 1,   IL5↓, 1,   Inflam↓, 2,   NF-kB↓, 3,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 2,   Dose↝, 1,   selectivity↑, 1,   Synergy↑, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 2,   TumVol↓, 1,   TumW↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 44

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 1,   GPx↑, 1,   GSH↑, 1,   GSR↑, 1,   MDA↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

CYP2C19↓, 1,   CYP2C9↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

TC↓, 1,  

Functional Outcomes(tgid=23) ⓘ

hepatoP↓, 1,   Sleep↑, 1,  
Total Targets: 13

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:523  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page